A Phase 3 interventional study of Dexamethasone and Placebo Vehicle in Chronic Allergic Conjunctivitis, sponsored by Ocular Therapeutix, Inc.. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-29.
Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of chronic allergic conjunctivitis
211 studies on the registry are indexed under Conjunctivitis, Allergic; 18 are open to participants now.
This study's enrollment of 73 is below the median of 87 across 174 interventional studies indexed under Conjunctivitis, Allergic.
Browse Conjunctivitis, Allergic studies →Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
Drug: Dexamethasone
PV (placebo drug delivery vehicle)
Other: Placebo Vehicle
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
Time frame: 3 minutes
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
Time frame: 5 minutes
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
Time frame: 7 minutes
Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
Time frame: 7 minutes
Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
Time frame: 15 minutes
Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
Time frame: 20 minutes
| Milestone | OTX-DP | Placebo Vehicle |
|---|---|---|
| Started | 35 | 38 |
| Completed | 33 | 37 |
| Not completed | 2 | 1 |
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
| units on a scale | OTX-DP | Placebo Vehicle |
|---|---|---|
| Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 | 1.68 ± 1.032 | 2.66 ± 0.861 |
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
| units on a scale | OTX-DP | Placebo Vehicle |
|---|---|---|
| Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 | 1.87 ± 1.040 | 2.74 ± 0.690 |
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
| units on a scale | OTX-DP | Placebo Vehicle |
|---|---|---|
| Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6 | 1.70 ± 0.938 | 2.74 ± 0.679 |
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
| units on a scale | OTX-DP | Placebo Vehicle |
|---|---|---|
| Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6 | 1.52 ± 0.641 | 1.80 ± 0.764 |
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
| units on a scale | OTX-DP | Placebo Vehicle |
|---|---|---|
| Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6 | 1.48 ± 0.698 | 1.75 ± 0.786 |
Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None
| units on a scale | OTX-DP | Placebo Vehicle |
|---|---|---|
| Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6 | 1.44 ± 0.710 | 1.76 ± 0.766 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OTX-DP | 0/35 (0%) | 0/35 (0%) | 3/35 (8.6%) |
| Placebo Vehicle | 0/38 (0%) | 0/38 (0%) | 4/38 (10.5%) |
| Event | OTX-DP | Placebo Vehicle |
|---|---|---|
| Adverse EventsGeneral disorders | 3/35 | 4/38 |
| Age, Continuous(years) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Mean | 38.2 (19 to 66) | 36.3 (18 to 62) | 37 (18 to 66) |
| Sex: Female, Male(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Female | 17 | 14 | 31 |
| Male | 18 | 24 | 42 |
| Ethnicity (NIH/OMB)(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 6 | 9 |
| Not Hispanic or Latino | 31 | 31 | 62 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 13 | 11 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 10 | 9 | 19 |
| White | 10 | 12 | 22 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 2 | 4 | 6 |
| Iris Color(Participants) | OTX-DP | Placebo Vehicle | Total |
|---|---|---|---|
| Blue | 4 | 1 | 5 |
| Brown | 26 | 32 | 58 |
| Hazel | 1 | 0 | 1 |
| Green | 4 | 5 | 9 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2015 to primary completion in Aug 2015, 4 months.
Results were first posted in Mar 2018, 2 years 7 months after primary completion.
Of 21 phase 3 interventional studies under Conjunctivitis, Allergic, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone